In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate

• Auteurs principaux: Thomas J. Griffin (Auteur), Ann Thanawastien (Auteur), Robert T. Cartee (Auteur), John J. Mekalanos (Auteur), Kevin P. Killeen (Auteur)
• Format: Livre
• Publié: Taylor & Francis Group, 2019-06-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Typhax is an investigational typhoid fever vaccine candidate that was GMP manufactured applying Protein Capsular Matrix Vaccine (PCMV) technology. It consists of Vi polysaccharide antigen, derived from S. Typhi, non-covalently entrapped in a glutaraldehyde catalyzed cross-linked α-poly-L-lysine and...